Stock News Summary: Endo International plc (NASDAQ:ENDP)

Endo International plc (NASDAQ:ENDP) stock observed trading -86.81% off 52-week high price. On the other end, the stock has been noted 14.02% away from low price over the last 52-weeks.The stock declared a move of -24.04% away from 50 day moving average and -66.19% away from 200 day moving average. Moving closer, we can see that shares have been trading -3.61% off 20-day moving average. It has market cap of $573.35M.

 On Sept. 04, 2019, Endo International plc (NASDAQ:ENDP)  declared that Novitium Pharma, LLC, a partner of Endo’s subsidiary Endo Ventures Limited, received approval from the U.S. Food and Drug Administration for a room temperature stable, AB-rated, generic equivalent of Swedish Orphan Biovitrum’s Orfadin®(nitisinone capsules).  Endo’s operating company Par Pharmaceutical expects to distribute the product through specialty pharmacies beginning this month.

Nitisinone capsules are indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

We are pleased to offer this rare patient population suffering from HT-1 the first and only bioequivalent and therapeutically equivalent option to Orfadin® capsules. Additionally, the product can be stored at room temperature which is an added convenience to patients, said Domenic Ciarico, Executive Vice President and Chief Commercial Officer, Sterile and Generics. We are proud to continue our tradition at Par of providing high quality, affordable medicines to patients.

Novitium has a history of impressive development and execution skills and we are pleased to have several products under development with them, said Brandon Rockwell, Senior Vice President of Business Development. This first time generic approval is another example of Par’s strategic investment in business development and execution on first-to-market and first-to-file products.

According to Swedish Orphan Biovitrum, global sales for Orfadin® were approximately $85M over the last four quarters.

 The Ireland based company Endo International plc moved with change of 2.52% to $2.44 with the total traded volume of 9875316 shares in recent session versus to an average volume of 6028.85K.The stock was observed in the 5 days activity at -4.31%. The one month performance of stock was -14.39%. ENDP’s shares are at -51.97% for the quarter and driving a -85.77% return over the course of the past year and is now at -66.58% since this point in 2018.  Right now the stock beta is 1.23. The average volatility for the week and month was at 9.37% and 13.14% respectively. There are 234.98M shares outstanding and 202.39M shares are floated in market.

Christopher Pacheco has worked as financial analyst until his retirement. He is a well-known research director and portfolio manager for more than 5 years. After many years in the market, he dedicated all his time to write articles highlighting different financial problems.

Christopher Pacheco holds a postgraduate degree in Software Engineering from Canada. ‘The stock market is filled with individuals who know the price of everything, but the value of nothing.’ Christopher is a share market expert, being personally invested for over 6 years. He believes the most valuable nugget of wisdom for new investors is a quote from Phillip Fisher. He has been writing his entire life, and while he has made a career of business and finance reporting, he still enjoys writing short stories and poetry.

Address: 25176 10th Street, Greenfield, CA 93927, USA

Email: [email protected]

Zip code: 93927

Contact # 831-385-8150

Leave a Reply

Your email address will not be published. Required fields are marked *